menu
    • menu
    [{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Meitheal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Meitheal Pharmaceuticals \/ Premier Inc","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier Inc"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Xentria","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"XTMAB-16","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Meitheal Pharmaceuticals","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Meitheal Pharmaceuticals \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Meitheal Pharmaceuticals \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Meitheal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Nanjing King-friend Biochemical Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Insulin aspart","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Meitheal Pharmaceuticals \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Meitheal Pharmaceuticals \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Fosfomycin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Meitheal Pharmaceuticals \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Meitheal Pharmaceuticals \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Nanjing King-friend Biochemical Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Meitheal Pharmaceuticals \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Meitheal Pharmaceuticals \/ Meitheal Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Meitheal Pharmaceuticals

    Menu

    Meitheal Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Nanjing King-friend Biochemical Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Meitheal Secures Licensing for XENLETA® to Expand Biopharmaceutical Portfolio

                            Details : Meitheal secured commercial rights in the U.S. to Xenleta (lefamulin acetate) through an exclusive license agreement with its parent company. It is indicated for the CABP in adults.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Nanjing King-friend Biochemical Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosfomycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Nabriva Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Meitheal Pharmaceuticals Expands Portfolio with Acquisition of CONTEPO™ from Nabriva

                            Details : Meitheal has acquired the North American rights to CONTEPO (fosfomycin) from Nabriva. CONTEPO is a novel, intravenous, broad-spectrum antibiotic used for the treatment of urinary tract infections.

                            Product Name : Contepo

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 18, 2024

                            Lead Product(s) : Fosfomycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Nabriva Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : Nanjing King-friend Biochemical Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.

                            Details : Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            September 21, 2023

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Nanjing King-friend Biochemical Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plerixafor

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meitheal Pharmaceuticals has Plerixafor Injection Now Available

                            Details : Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.

                            Product Name : Plerixafor-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 02, 2023

                            Lead Product(s) : Plerixafor

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XTMAB-16

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Recipient : Xentria

                            Deal Size : $680.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America

                            Details : Under the agreement, Meitheal gains exclusive rights to commercialize XTMAB-16, a monoclonal antibody which aims to treat people with sarcoidosis, in North America and Xentria remains responsible for clinical development and retains the marketing rights ...

                            Product Name : XTMAB-16

                            Product Type : Large molecule

                            Upfront Cash : $45.0 million

                            June 27, 2023

                            Lead Product(s) : XTMAB-16

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Xentria

                            Deal Size : $680.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Premier

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meitheal Pharmaceuticals Announces Findings from Collaborative Research Study with Premier Inc. Evaluating Ant...

                            Details : Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2021

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Premier

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States

                            Details : Meitheal Pharmaceuticals has launched Enoxaparin Sodium Injection, generic equivalent of Lovenox®, in the United States market. Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharma...

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 28, 2020

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth